Tiziana Life Sciences (TLSA) announced a significant milestone in its clinical development program for Alzheimer’s disease. The Company has successfully dosed the first patient with moderate Alzheimer’s disease using intranasal foralumab at Brigham and Women’s Hospital in Boston, Massachusetts following on from their baseline PET scan.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Expands MS Clinical Trial Network
- Tiziana Life Sciences expands Phase 2 trial for non-active SPMS
- Tiziana Life Sciences Secures ALS Trial Funding
- Tiziana Life Sciences announces ALS trial grant awarded by ASL Association
- Tiziana Life Sciences Highlights Advancements at BIO-Europe 2024